Literature DB >> 33613532

CCR8 Signaling via CCL1 Regulates Responses of Intestinal IFN-γ Producing Innate Lymphoid CelIs and Protects From Experimental Colitis.

Le Kang1, Angelika Schmalzl1, Tamara Leupold1, Miguel Gonzalez-Acera1, Raja Atreya1, Markus F Neurath1,2, Christoph Becker1,2, Stefan Wirtz1,2.   

Abstract

A diverse spectrum of immune cells populates the intestinal mucosa reflecting the continuous stimulation by luminal antigens. In lesions of patients with inflammatory bowel disease, an aberrant inflammatory process is characterized by a very prominent infiltrate of activated immune cells producing cytokines and chemokines. These mediators perpetuate intestinal inflammation or may contribute to mucosal protection depending on the cellular context. In order to further characterize this complex immune cell network in intestinal inflammation, we investigated the contribution of the chemokine receptor CCR8 to development of colitis using a mouse model of experimental inflammation. We found that CCR8-/- mice compared to wildtype controls developed strong weight loss accompanied by increased histological and endoscopic signs of mucosal damage. Further experiments revealed that this gut protective function of CCR8 seems to be selectively mediated by the chemotactic ligand CCL1, which was particularly produced by intestinal macrophages during colitis. Moreover, we newly identified CCR8 expression on a subgroup of intestinal innate lymphoid cells producing IFN-γ and linked a functional CCL1/CCR8 axis with their abundance in the gut. Our data therefore suggest that this pathway supports tissue-specific ILC functions important for intestinal homeostasis. Modulation of this regulatory circuit may represent a new strategy to treat inflammatory bowel disease in humans.
Copyright © 2021 Kang, Schmalzl, Leupold, Gonzalez-Acera, Atreya, Neurath, Becker and Wirtz.

Entities:  

Keywords:  CCR8; chemokines; cytokines; inflammatory bowel disease; innate immunity; innate lymphoid cell

Year:  2021        PMID: 33613532      PMCID: PMC7892458          DOI: 10.3389/fimmu.2020.609400

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  58 in total

1.  Biased agonism as a mechanism for differential signaling by chemokine receptors.

Authors:  Sudarshan Rajagopal; Daniel L Bassoni; James J Campbell; Norma P Gerard; Craig Gerard; Tom S Wehrman
Journal:  J Biol Chem       Date:  2013-10-21       Impact factor: 5.157

2.  CCL17 promotes intestinal inflammation in mice and counteracts regulatory T cell-mediated protection from colitis.

Authors:  Alexander F Heiseke; Antonia C Faul; Hans-Anton Lehr; Irmgard Förster; Roland M Schmid; Anne B Krug; Wolfgang Reindl
Journal:  Gastroenterology       Date:  2011-11-02       Impact factor: 22.682

3.  Identification of CCR8, the receptor for the human CC chemokine I-309.

Authors:  R S Roos; M Loetscher; D F Legler; I Clark-Lewis; M Baggiolini; B Moser
Journal:  J Biol Chem       Date:  1997-07-11       Impact factor: 5.157

4.  Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice.

Authors:  R Ito; M Shin-Ya; T Kishida; A Urano; R Takada; J Sakagami; J Imanishi; M Kita; Y Ueda; Y Iwakura; K Kataoka; T Okanoue; O Mazda
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

5.  Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ T(H)2 cells.

Authors:  Sabina A Islam; Daniel S Chang; Richard A Colvin; Mike H Byrne; Michelle L McCully; Bernhard Moser; Sergio A Lira; Israel F Charo; Andrew D Luster
Journal:  Nat Immunol       Date:  2011-01-09       Impact factor: 25.606

Review 6.  Biased agonism at chemokine receptors: obstacles or opportunities for drug discovery?

Authors:  Caroline A Anderson; Roberto Solari; James E Pease
Journal:  J Leukoc Biol       Date:  2015-12-23       Impact factor: 4.962

7.  Identification of human CCR8 as a CCL18 receptor.

Authors:  Sabina A Islam; Morris F Ling; John Leung; Wayne G Shreffler; Andrew D Luster
Journal:  J Exp Med       Date:  2013-09-02       Impact factor: 14.307

8.  Indoleamine 2,3-Dioxygenase Fine-Tunes Immune Homeostasis in Atherosclerosis and Colitis through Repression of Interleukin-10 Production.

Authors:  Sarvenaz Metghalchi; Padmapriya Ponnuswamy; Tabassome Simon; Yacine Haddad; Ludivine Laurans; Marc Clément; Marion Dalloz; Mélissa Romain; Bruno Esposito; Vincent Koropoulis; Bruno Lamas; Jean-Louis Paul; Yves Cottin; Salma Kotti; Patrick Bruneval; Jacques Callebert; Hester den Ruijter; Jean-Marie Launay; Nicolas Danchin; Harry Sokol; Alain Tedgui; Soraya Taleb; Ziad Mallat
Journal:  Cell Metab       Date:  2015-07-30       Impact factor: 27.287

9.  Unique and redundant functions of NKp46+ ILC3s in models of intestinal inflammation.

Authors:  Christina Song; Jacob S Lee; Susan Gilfillan; Michelle L Robinette; Rodney D Newberry; Thaddeus S Stappenbeck; Matthias Mack; Marina Cella; Marco Colonna
Journal:  J Exp Med       Date:  2015-10-12       Impact factor: 14.307

10.  Divergent Roles of Interferon-γ and Innate Lymphoid Cells in Innate and Adaptive Immune Cell-Mediated Intestinal Inflammation.

Authors:  Jennifer Brasseit; Cheong K C Kwong Chung; Mario Noti; Daniel Zysset; Nina Hoheisel-Dickgreber; Vera Genitsch; Nadia Corazza; Christoph Mueller
Journal:  Front Immunol       Date:  2018-01-24       Impact factor: 7.561

View more
  1 in total

Review 1.  Heterogeneity of ILC2s in the Intestine; Homeostasis and Pathology.

Authors:  Shogo Sunaga; Junya Tsunoda; Toshiaki Teratani; Yohei Mikami; Takanori Kanai
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.